The FDA's Stifling Grip: Kintsugi's AI for Depression Detection Fails to Launch
1 min read
Product Design, UX & Human-Centered AI
-/5
In short
- Let’s be clear: the FDA is a barrier to innovation.
- Kintsugi, a promising startup, has spent seven years developing AI to detect depression and anxiety through speech.
- They had the potential to change lives, but the FDA clearance process crushed their dreams.
Let’s be clear: the FDA is a barrier to innovation. Kintsugi, a promising startup, has spent seven years developing AI to detect depression and anxiety through speech. They had the potential to change lives, but the FDA clearance process crushed their dreams. Now, they’re shutting down and releasing their technology as open-source. This is a wake-up call! If you ignore this, you lose time. The healthcare industry needs to adapt and embrace technology that can save lives. Who's moving ahead? Those who are willing to challenge the status quo. Who's falling behind? Companies shackled by outdated regulations. This changes the game. We must demand faster pathways for life-saving innovations. The time for action is now!
Source:
-
It’s not easy to get depression-detecting AI through the FDA — The Verge (EN-US)